Annals of Oncology Гематология
Atirmociclib and fulvestrant for patients with HR-positive/HER2-negative advanced or metastatic breast cancer who progressed on a prior cyclin-dependent kinase 4/6 inhibitor: primary analysis of the randomized FourLight-1 trial☆
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.